Easton Pharmaceuticals Announces Three New Additional Products and a Revision to Its Viorra Flagship Product Towards Resuming Its Latin American & South East Asia Initiatives
Fourth Product is Anticipated for Its Proposed Medical Marijuana Initiatives
Easton Pharmaceuticals (OTC:EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces that its restructuring of management, business strategy and products has resulted in the company being able to re-start initiatives and discussions on its main Viorra product and the addition of 3 new products for both the North and Latin American markets, including Mexico and various parts of South East Asia.
Through the recent appointment of new directors, consultants and key personnel who have yet to be formally announced, The company has reformulated various parts of its product line starting with its flagship product "Viorra" and its transdermal delivery system. In addition the company has introduced three new OTC products. The company is pleased to announce a topical OTC wound healing product, a topically applied pain gel and a motion sickness product, all based around and encompassing hyaluronic Acid as its main active ingredient. Additional information and details on these 3 new products including final packaging and how they can be obtained will be made known shortly.
A fourth product is presently in the process to be hopefully added to the current line of products which deals towards the recently announced medical marijuana initiatives in North America. This proposed product will also have opportunities in Mexico and Latin America who are thought to have more relaxed laws related to medical marijuana compared to North America. The company believes medical marijuana may have more short term potential than what presently exists in North America, although new laws and guidelines are expected to be announced in both the United States and Canada after a recent adjournment by law makers a few months ago.
After a delay to its revised formulations on Viorra, the company is ready to resume all discussions and initiatives in various parts of Latin America including Mexico and possibly certain parts of South East Asia. Easton will be utilizing consultants as well as having the assistance of Mr. Neil Mellor and his vast industry experience and knowledge.
The company is presently in the process of ordering active ingredients for Viorra and to create a certain allotment of batch samples including the three new product additions and final packaging with the intent of having the samples shipped to distributors in Latin America including Mexico. Easton’s third party consultants believes there exists a strong demand and substantial opportunities in these markets for these types of products, especially Viorra which is the reason it is initially placing its main focus on these foreign markets. The process is to start with delivering samples including a final packaged product and literature for a presentation to potential respected distributors. It must then follow an approval protocol which is considered considerably shorter than in North America.
The company regrets the delays over the past year, but the delays were mostly as a result of its management reorganization and new formulations in its flagship products which needed to preserve ingredients that would continue to be classified as GRAS (generally regarded as safe) as per FDA guidelines. Latin America and South East Asia possesses a population upwards of 4 Billion people. The Over The Counter aspect of VIORRA and the fact the product possesses ingredient’s classified by the FDA as GRAS (generally regarded as safe) has transformed VIORRA into a very appealing product to people in these markets who repeatedly use over the counter products / herbal remedies than is the case in North American society. Products such as this have wide appeal and attraction to people in Latin America and East Asian culture, which includes large markets such as China and India.
Additional updates on its 3 new products will be made available on subsequent releases and website updates.
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to female and male sexual dysfunction, treatment of certain pain, wound healing, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's updated gel formulation is an innovative and thought to be unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.